Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Metabolic-dysfunction Associated Steatotic Liver Disease
View Full LandscapeTarget Indication
Metabolic-dysfunction Associated Steatotic Liver Disease
Clinical Trial
NCT07459504Last updated: 8/21/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Maapliv
Maapliv is indicated for the treatment of maple syrup urine disease (MSUD) presenting with an acute decompensation episode in patients from birth who are not eligible for an oral and enteral branched-chain amino acids free (BCAA- free) formulation.